Summary
Patients with metastatic melanoma who are overweight or obese have improved outcomes when treated with immunotherapies or targeted therapies. A recent study provides the first evidence that the host metabolic state influences the tumor metabolic phenotype, with implications for tumor progression and therapeutic response.
©2022 American Association for Cancer Research
2022
American Association for Cancer Research
You do not currently have access to this content.